Novartis Found Symposium 234

ISBN-13: 9780471494379 / Angielski / Twarda / 2001 / 296 str.

William MacNee;Novartis Foundation Symposium

Opis

Chronic obstructive pulmonary disease, characterized by progressive chronic airflow obstruction, is a common respiratory disorder and cause of death in adults, but has received little attention compared with other respiratory diseases such as asthma and lung cancer. Current treatment offers some symptomatic relief, but does not address the underlying process. As smoking cessation is the only intervention known to alter the rate of disease progression, there is a great need for the development of superior therapies for symptomatic relief and disease modification. This book reviews and discusses the most recent advances in the understanding of the disorder and draws together basic and clinical aspects relevant to the topic with much new and exciting work in the area. It identifies and stimulates promising new research directions.

Recenzje

"The panel of speakers included some of the most distinguished scientists and physicians working in the field of COPD."(Biochemie, No. 83, 2001)

Spis treści

Overview of the pathology/pathogenesis
Overview of current therapies
Genetics
Mucus hypersecretion in COPD
Mechanisms of exacerbation
Epithelial and mesenchymal cells
Macrophage control of inflammation: negative pathways of regulation of inflammatory cytokines
Neutrophils
Lymphocytes
Oxidants/antioxidants
Proteases and anti–proteases –
I
Proteases and anti–proteases –
II
Alveolus formation: critical period, plasticity and retinoid regulation
Systemic effects of COPD
Potential novel therapies for COPD

Blurb

Chronic obstructive pulmonary disease (COPD) is the most common respiratory disorder of adults in the developed world and is the fourth main cause of death in the USA. It is also associated with high morbidity, and poses an enormous burden of suffering and expense. Despite this, the disease has received little attention compared with other respiratory conditions such as asthma and lung cancer.

Current treatment can offer some marginal symptomatic relief but does not address the underlying disease process. Indeed, smoking cessation is the only intervention known to alter the rate of disease progression. There is clearly great need, and potential, for the development of superior therapies for symptomatic relief and disease modification. This book brings together leading researchers and physicians to discuss the most recent advances in our understanding of COPD, and draws together basic and clinical aspects relevant to the topic. Coverage includes the basic pathology, current and potential therapies, and detailed consideration of the major theories for the pathogenesis of COPD.